AI-Driven Molecular Design for the Future of Biotech

At Rare Molecule Foundry (RMF), we harness the power of advanced AI models to design molecules, proteins, enzymes, and peptides in silico.

Engineering the Future of Molecular Innovation

At Rare Molecule Foundry (RMF), we design molecules, proteins, enzymes, and peptides in-silico using cutting-edge AI models. Our proprietary technology accelerates the discovery and optimization of novel compounds for biopharma, research, and drug development—reducing time, cost, and uncertainty in the innovation pipeline.

Whether you’re developing next-generation therapeutics, advancing synthetic biology, or exploring novel biomaterials, RMF provides the computational power to model, refine, and validate molecular structures before they reach the lab.

From concept to candidate, we bring precision-driven design to molecular engineering—helping you build the future of science.

Why Rare Molecule Foundry?

Ready to accelerate discovery and push the boundaries of science?

AI-Powered Molecular Design

We leverage advanced AI-driven models to generate and refine novel molecules with unprecedented speed and accuracy—reducing trial-and-error experimentation.

01

Accelerated Drug Discovery & Biodesign

Our computational platform helps biopharma and research teams identify viable candidates faster, optimizing for stability, efficacy, and manufacturability before synthesis.

02

Precision-Driven Innovation

We design molecules tailored to specific functions, whether for therapeutics, enzymatic engineering, or synthetic biology applications—ensuring targeted, high-performance solutions.

03

Seamless Integration with R&D Pipelines

RMF’s computational approach complements traditional wet lab research, streamlining workflows and bridging the gap between theory and experimentation.

04

Speed. Efficiency. Impact.

By unlocking new frontiers in molecular engineering, RMF empowers teams to push the boundaries of science—faster, smarter, and with greater confidence.

05

Let’s Build the Future of Molecular Innovation

Whether you’re a biotech startup, a pharmaceutical leader, or a research institution, Rare Molecule Foundry is your partner in AI-driven molecular design.
Ready to accelerate discovery and push the boundaries of science?

Let’s collaborate. Contact us today to explore how RMF can power your next breakthrough.

Our Projects

Gap Junction Modulators

Utilizing generative AI, we’re designing molecules that can modulate gap junctions—crucial for intercellular communication. Applications include regenerative medicine, cardiac therapies, oncology, and aging.

Multifaceted Therapeutics for Neurodegenerative Diseases

Developing diverse molecules targeting multiple pathways involved in neurodegeneration, offering hope for treating Parkinson’s and Alzheimer’s, especially in early-onset cases.

Advanced Oncology Therapeutics

Pioneering cancer treatments, including protein binders targeting specific cancer-related proteins for inhibition, drug conjugates, and immune cell engagement.

Industrial Enzymes for Biorecycling

Developing AI-powered enzyme design workflows to optimize and create enzymes for breaking down plastics, contributing to a sustainable biorecycling economy.

Enzymatic Solutions for Food Manufacturing

Enhancing enzymes in food production through AI-driven iterative design, improving catalytic activity and efficiency in food manufacturing processes.

Octopus Toxin Antidote

Designing AI-driven proteins to sequester tetrodotoxin, a potent neurotoxin found in blue-ringed octopus venom, aiming to develop an effective antidote.

Avian Flu Inhibitor

Developing a novel inhibitor to prevent avian influenza infection in host cells, designed for nasal spray delivery to reduce symptoms and transmission rates.

Proudly Supported By:
42p Ventures

Our process is designed to guide you every step of the way. From initial consultation to personalized strategy development.

The Team

Chris Wilson

Co-Founder & CEO

Amelie Schreiber

Co-Founder & Head of Molecular Engineering

Stanley Bishop

Co-Founder & Chief Scientific Officer